Instrument Inactif

Communiqués SoftOx Solutions AS Oslo Bors

Actions

NO0010811961

Recherche biotechnologique et médicale

Communiqués

27/08	SoftOx Solutions AS: New Share Capital	AQ
11/08	SoftOx Solutions AS: FIRST PATIENT DOSED IN SIS-03 PROOF-OF-CONCEPT PATIENT TRIAL	AQ
26/06	SoftOx Solutions AS: POSITIVE TOPLINE SAFETY DATA FROM SIS-03 DOSE-ESCALATION PHASE	AQ
24/06	SoftOx Solutions AS: First Quarter Report 2026	AQ
18/06	SoftOx Solutions AS: New Share Capital	AQ
09/06	SoftOx Solutions AS: Notice of General Assembly	AQ
09/06	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
08/06	SoftOx Solutions AS: SIS-03 DOSE-ESCALATION PHASE COMPLETED AND INITIATION OF PROOF-OF-CONCEPT PHASE	AQ
05/06	SoftOx Solutions AS: FIRST PARTICIPANT ENROLLED IN BIODEFENCE-FOCUSED SIS-02 PHASE 1 CLINICAL STUDY	AQ
27/05	SoftOx Solutions AS: Annual Report 2025	AQ
21/04	SoftOx Solutions AS: New Share Capital	AQ
13/04	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
25/03	SoftOx Solutions AS: Fourth Quarter Report 2025	AQ
24/03	SoftOx Solutions AS: New Share Capital	AQ
11/03	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
03/03	SoftOx Solutions AS: First Subject Dosed in Combined Phase 2a Dose-Escalation and Proof-of-Concept Trial (SIS-03)	AQ
25/02	SoftOx Defense Solutions AS: HPRA Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy	AQ
04/02	SoftOx Solutions AS: New Share Capital	AQ
23/01	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
29/12	SoftOx Solutions AS: Danish Medicines Agency Approves Phase 2a Trial for SoftOx Inhalation Solution	AQ
05/12	SoftOx Solutions AS: New Share Capital	AQ
28/11	SoftOx Solutions AS: Notice of Extraordinary General Assembly	AQ
28/11	SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited	AQ
26/11	SoftOx Solutions AS: Third Quarter Report 2025	AQ
14/11	SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured – Key Milestone for CF and EDF Clinical Programs	PU